Transcat (NASDAQ:TRNS) Upgraded to “Strong-Buy” at Zacks Research

Transcat (NASDAQ:TRNS) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday, Zacks reports.

A number of other analysts have also commented on TRNS. CJS Securities assumed coverage on shares of Transcat in a research note on Tuesday, October 27th. They set an “outperform” rating and a $115.00 price objective for the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Transcat in a research report on Tuesday, August 25th. Oppenheimer raised Transcat from a “market perform” rating to an “outperform” rating and set a $115.00 price target for the company in a research report on Wednesday. Finally, Northland Securities upgraded shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Transcat currently has an average rating of “Moderate Buy” and a consensus target price of $108.33.

Transcat Price Performance

NASDAQ:TRNS traded up $1.13 during midday trading on Thursday, hitting $101.51. 169,759 shares of the stock were exchanged, compared to its average volume of 135,380. Transcat has a one year low of $50.23 and a one year high of $110.47. The company has a current ratio of 2.49, a quick ratio of 2.11 and a debt-to-equity ratio of 0.36. The business has a 50-day moving average price of $86.94 and a two-hundred day moving average price of $82.43. The company has a market capitalization of $953.18 million, a price-to-earnings ratio of 211.48 and a beta of 0.61.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings data on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.19. Transcat had a return on equity of 5.56% and a net margin of 0.99%. The business had revenue of $97.09 million during the quarter, compared to analyst estimates of $92.46 million. Sell-side analysts predict that Transcat will post 2.06 EPS for the current year.

Insider Activity

In related news, CEO Jaime A. Irick purchased 2,275 shares of the stock in a transaction on Thursday, November 5th. The shares were purchased at an average cost of $101.26 per share, for a total transaction of $230,366.50. Following the completion of the transaction, the chief executive officer directly owned 2,275 shares of the company’s stock, valued at approximately $230,366.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Transcat

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRNS. Integrated Wealth Concepts LLC bought a new stake in Transcat during the 2nd quarter worth approximately $32,000. Persistent Asset Partners Ltd acquired a new stake in shares of Transcat during the second quarter worth $52,000. GAMMA Investing LLC lifted its stake in Transcat by 133.6% in the third quarter. GAMMA Investing LLC now owns 1,030 shares of the scientific and technical instruments company’s stock valued at $91,000 after buying an additional 589 shares during the period. Canada Pension Plan Investment Board bought a new position in Transcat during the second quarter worth about $204,000. Finally, The Manufacturers Life Insurance Company bought a new position in Transcat during the second quarter worth about $226,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

More Transcat News

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Zacks upgraded Transcat to Rank #1 (Strong Buy), citing improving earnings prospects, and included TRNS on its Strong Buy momentum-stock list. Zacks Strong Buy upgrade
• Positive Sentiment: Northland Securities raised its EPS forecasts across 2027–2031, including lifting its FY2027 estimate to $2.00 from $1.71 and its FY2031 estimate to $3.69 from $3.53. The revisions suggest stronger expected earnings growth. Northland estimate revisions
• Positive Sentiment: Oppenheimer raised its rating on Transcat to Outperform, adding to the favorable analyst sentiment. Oppenheimer rating upgrade
• Positive Sentiment: Recent coverage linked TRNS reaching a 52-week high to an earnings beat and improved outlook. The supplied background also reports quarterly EPS of $0.64 versus a $0.45 consensus estimate, with revenue above forecasts. Transcat 52-week high following earnings beat
• Neutral Sentiment: Northland maintained an Outperform rating but set a $95 price target, below the $101.32 share price cited in the background; this may temper the impact of its higher earnings forecasts. Northland rating and target

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.